BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for bisoprolol fumarate; hydrochlorothiazide and what is the scope of freedom to operate?
Bisoprolol fumarate; hydrochlorothiazide
is the generic ingredient in two branded drugs marketed by Actavis Elizabeth, Apothecon, Aurobindo Pharma Ltd, Cadila, Chartwell Rx, Edenbridge Pharms, Epic Pharma Llc, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Mylan, Novitium Pharma, Teva, Unichem, Unique Pharm, Watson Labs Teva, and Teva Branded Pharm, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.Twelve suppliers are listed for this compound.
Summary for BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 16 |
| NDAs: | 16 |
| Finished Product Suppliers / Packagers: | 12 |
| DailyMed Link: | BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE at DailyMed |
Pharmacology for BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
| Drug Class | Thiazide Diuretic beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
US Patents and Regulatory Information for BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
Expired US Patents for BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-003 | Mar 26, 1993 | 4,258,062 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch